<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=384506&amp;fmt=gif">
Skip to content
Search
{
Book a Demo
    Book a Demo
      Share

      Lorem Ipsum Dolor Sit Amet

      Download
      Download
      Case Study | April 9, 2025

      Improving AMR Research with Smarter Drug Discovery Data Management: A BioVersys Case Study

      BioVersys Drug Discovery Data Management Case Study

      Introduction to BioVersys Drug Discovery Data Management

      This case study explores how BioVersys transformed its data processes using CDD Vault to streamline collaboration, support regulatory demands, and enable real-time insight sharing across its AMR pipeline.

      As the global crisis of antimicrobial resistance (AMR) intensifies, innovative biotech companies are stepping in to fill the gap left by large pharmaceutical firms. Swiss-based BioVersys is at the forefront of this movement, building solutions to combat drug-resistant infections with targeted, next-generation antimicrobials. But with high-stakes projects spanning multiple countries and partners, effective drug discovery data management has become a critical requirement—not just for speed and accuracy, but for survival.

      Findings: AMR & Drug Discovery Data Management

      The path to discovering new antibiotics is fraught with financial, logistical, and technical hurdles. Part of the challenge lies in managing cross-functional teams working across multiple countries and disciplines. In its early days, BioVersys operated on a small scale where data could be tracked manually. But as its pipeline matured and expanded, the company recognized that traditional tools were no longer sufficient. The lack of a scalable, structured system for drug discovery data management began to hinder progress.

      At the same time, BioVersys’ work in AMR surveillance and development of treatments targeting MRSA, TB, and Acinetobacter baumannii required rigorous, real-time tracking of antibiotic resistance data. To stay ahead in the fight against resistant infections, they needed a system that could unify teams, ensure data integrity, and support the fast-paced evolution of AMR data from discovery through clinical trials.

      “Antimicrobials are a cornerstone of modern medicine. But just like we take electricity for granted, we’ve assumed antibiotics will always be available. That assumption no longer holds.”

      - Andrej Trauner, Project Manager, BioVersys

      Find out how CDD Vault can support Drug Discovery Data Management

      Get Started

      Find out how CDD Vault can support Drug Discovery Data Management

      As BioVersys grew, its manual methods of tracking data began to break down under the weight of multiple global projects. Implementing CDD Vault gave the company a flexible, secure, and scalable foundation for effective drug discovery data management.

      • Early systems relied on individuals manually updating experimental results and databases.
      • As teams expanded, keeping data current became time-consuming and error-prone.
      • BioVersys implemented CDD Vault to centralize chemical, biological, and clinical information in a structured format.
      • The new system allowed multiple users to input and retrieve data in real time, streamlining internal workflows and collaboration.

      “We rely on our data management processes and infrastructure to ensure that we capture all of our data, enhance internal communication, and empower teams to generate insights.”

      - Andrej Trauner, Project Manager

      Managing MRSA Projects Across Borders

      One of BioVersys' most urgent programs targets MRSA, a leading cause of death related to antimicrobial resistance. The ability to seamlessly share compound, assay, and toxicity data across four countries became possible with the help of CDD Vault.

      • The MRSA initiative involved collaboration between sites in Switzerland and France, with supporting partners across Europe.
      • CDD Vault enabled consistent data formatting, allowing side-by-side comparisons of in vitro potency, pharmacokinetics, and toxicity data.
      • Having structured access to real-time and historical data ensured more confident decision-making in lead optimization stages.
      • The platform enabled effective sharing of antibiotic resistance data relevant to this and other bacterial targets.

      Supporting AMR Surveillance and Data Transparency

      For companies developing antibiotics, contributing to global AMR surveillance efforts requires both speed and traceability. With CDD Vault, BioVersys ensured that its AMR data could be securely accessed, version-controlled, and transparently reported.

      • CDD Vault supports internal tracking of compound resistance profiles, including historical AMR data trends.
      • Visualization tools, including dose-response curves and searchable substructure features, helped teams identify blind spots in datasets.
      • The team could quickly share and interpret data during cross-partner discussions and consortia meetings.
      • The platform also made it easier to comply with data-sharing expectations from public and non-profit collaborators.

      “We aim to generate databases that span disciplines so we can cross-reference data, find correlations, and identify issues before they become problems.”

      Unifying Research for Greater Antibiotic Impact

      BioVersys is part of several international collaborations, and its future depends on transparency and alignment with global stakeholders. With a system designed for collaborative workflows, CDD Vault helped unify drug discovery data management and reporting across projects.

      • Participating in initiatives like CARB-X and the Innovative Medicines Initiative requires strict data governance.
      • CDD Vault provided the flexibility to adapt data models for different funding partners and research consortia.
      • Even non-specialists could navigate datasets thanks to intuitive visualization and curve-fitting tools.
      • This level of usability promotes inclusivity across public-private partnerships fighting antimicrobial resistance.

      “It would be almost impossible to develop a new product without close interaction between the private and public sectors. In that respect, the future of antimicrobial development is collaborative.”

      Conclusion

      As antimicrobial resistance threatens global health, companies like BioVersys are proving that innovation doesn’t end with drug development—it extends to how research is managed and shared. With CDD Vault, BioVersys has built a scalable foundation for efficient, collaborative, and transparent drug discovery data management that supports everything from early screening to clinical readiness.

      The ability to track, cross-reference, and securely share AMR data in real time has helped BioVersys advance its mission: creating novel therapeutics for the world’s most dangerous resistant infections. From MRSA to tuberculosis, BioVersys is accelerating progress in one of the most critical areas of modern medicine.

      Recommendations

      To effectively combat the rising tide of antimicrobial resistance, research organizations—especially small to mid-sized biotechs—should prioritize implementing flexible and centralized drug discovery data management systems.

      Platforms like CDD Vault not only improve operational efficiency but also enhance collaboration across teams and consortia focused on AMR surveillance and the integration of high-value antibiotic resistance data.

      In a field where timely insight and global cooperation are essential, having the right infrastructure in place can mean the difference between reactive research and proactive impact.

      References / Bibliography

      Additional Resources

      View All Posts
      CDD Vault Updates
      4 min   April 25, 2025
      CDD Vault Update (April 2025 #3): AI+ Folding and Docking
      Read More
      CDD Vault Updates
      10 min   April 18, 2025
      CDD Vault Update (April 2025 #2): Pharmacokinetic (PK) and Michaelis-Menten Kinetics (Km/Kd) Curve Fit Equations, Donut Charts, TIFF Image Previews, and Parallel Reactions
      Read More
      CDD Blog
      3 min   April 14, 2025
      Let’s Talk Security - Why a Bug Bounty May Be More Valuable Than a Penetration Test
      Read More

      Ready to get started?

      Our friendly team will show you how easy it is to enhance your data workflow with CDD Vault.

      Get A Personalized Demo